Platelet factor 4 regulates T cell effector functions in malignant pleural effusions

Area of Science:

• Immunology
• Oncology
• Pulmonology

Background:

• Malignant pleural effusion (MPE) is a critical complication of advanced lung adenocarcinoma (LAC).
• Understanding the tumor immune microenvironment in MPE is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the role of immunomodulatory factors in the MPE of LAC patients.
• To assess the impact of MPE on T cell function and correlate findings with prognosis.

Main Methods:

• ELISA was used to quantify immunomodulatory factors in MPE from LAC and heart failure (HF) patients.
• Flow cytometry analyzed T cell proliferation, cytotoxicity, and cytokine production when stimulated with pleural fluids.
• Correlation analyses examined relationships between factors and T cell function, and prognosis.

Main Results:

• MPE from LAC showed elevated levels of Platelet Factor 4 (PF4), VEGF, TGF-β, and P-selectin compared to HF.
• LAC pleural fluids suppressed T lymphocyte proliferation, cytotoxicity, and IL-17 production.
• PF4 levels inversely correlated with T cell function and were associated with poor prognosis in MPE.

Conclusions:

• Elevated PF4 in MPE contributes to tumor progression by inducing T cell dysfunction.
• Targeting PF4 may represent a therapeutic strategy for managing lung adenocarcinoma with MPE.